290 related articles for article (PubMed ID: 26458440)
1. [Epigenetic therapy for hematologic malignancies].
Kobayashi Y
Rinsho Ketsueki; 2015 Oct; 56(10):2015-23. PubMed ID: 26458440
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors.
Ungerstedt JS
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30304859
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.
Zhao A; Zhou H; Yang J; Li M; Niu T
Signal Transduct Target Ther; 2023 Feb; 8(1):71. PubMed ID: 36797244
[TBL] [Abstract][Full Text] [Related]
5. Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies.
Fratta E; Montico B; Rizzo A; Colizzi F; Sigalotti L; Dolcetti R
Oncotarget; 2016 Aug; 7(35):57327-57350. PubMed ID: 27329599
[TBL] [Abstract][Full Text] [Related]
6. DNA methyltransferases in hematologic malignancies.
Li KK; Luo LF; Shen Y; Xu J; Chen Z; Chen SJ
Semin Hematol; 2013 Jan; 50(1):48-60. PubMed ID: 23507483
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylases and epigenetic therapies of hematological malignancies.
Mercurio C; Minucci S; Pelicci PG
Pharmacol Res; 2010 Jul; 62(1):18-34. PubMed ID: 20219679
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic therapy in hematological cancers.
Dimopoulos K; Grønbaek K
APMIS; 2019 May; 127(5):316-328. PubMed ID: 30859683
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation as a therapeutic target in hematologic disorders: recent results in older patients with myelodysplasia and acute myeloid leukemia.
Rüter B; Wijermans PW; Lübbert M
Int J Hematol; 2004 Aug; 80(2):128-35. PubMed ID: 15481440
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic regulation in myelodysplastic syndromes: implications for therapy.
Vigna E; Recchia AG; Madeo A; Gentile M; Bossio S; Mazzone C; Lucia E; Morabito L; Gigliotti V; Stefano LD; Caruso N; Servillo P; Franzese S; Fimognari F; Bisconte MG; Gentile C; Morabito F
Expert Opin Investig Drugs; 2011 Apr; 20(4):465-93. PubMed ID: 21381982
[TBL] [Abstract][Full Text] [Related]
11. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Stahl M; Gore SD; Vey N; Prebet T
Expert Opin Investig Drugs; 2016; 25(3):307-17. PubMed ID: 26807602
[TBL] [Abstract][Full Text] [Related]
12. [A primer for epigenetics of hematological malignancies].
Nakajima H
Rinsho Ketsueki; 2016; 57(10):1835-1844. PubMed ID: 27725578
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents.
Claus R; Almstedt M; Lübbert M
Semin Oncol; 2005 Oct; 32(5):511-20. PubMed ID: 16210092
[TBL] [Abstract][Full Text] [Related]
14. The use of hypomethylating agents in the treatment of hematologic malignancies.
Kihslinger JE; Godley LA
Leuk Lymphoma; 2007 Sep; 48(9):1676-95. PubMed ID: 17786703
[TBL] [Abstract][Full Text] [Related]
15. DNA demethylating agents and epigenetic therapy of cancer.
Mani S; Herceg Z
Adv Genet; 2010; 70():327-40. PubMed ID: 20920754
[TBL] [Abstract][Full Text] [Related]
16. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
Jhanwar SC
Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic epigenetics: an emerging clinical approach to hematologic malignancies.
Clin Adv Hematol Oncol; 2005 Mar; 3(3 Suppl 1):1-10; quiz 11-2. PubMed ID: 21438190
[No Abstract] [Full Text] [Related]
18. Epigenetic programming contributes to development of drug resistance in hematological malignancies.
Wang QY; Zhong H
Front Biosci (Landmark Ed); 2015 Jan; 20(4):728-42. PubMed ID: 25553475
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic mechanisms in AML - a target for therapy.
Oki Y; Issa JP
Cancer Treat Res; 2010; 145():19-40. PubMed ID: 20306243
[TBL] [Abstract][Full Text] [Related]
20. [Epigenetics in hematological disorders].
Furukawa Y
Rinsho Ketsueki; 2008 Oct; 49(10):1472-82. PubMed ID: 18833931
[No Abstract] [Full Text] [Related]
[Next] [New Search]
